Anti-wrinkle composition, application thereof and cosmetic

Abstract

The invention relates to an anti-wrinkle composition, application thereof and cosmetics, the anti-wrinkle composition comprises ginsenoside CK and low-molecular-weight sodium hyaluronate, the mass ratio of the ginsenoside CK to the low-molecular-weight sodium hyaluronate is 1: (5-100), and the molecular weight of the low-molecular-weight sodium hyaluronate does not exceed 5000 Daltons. The anti-wrinkle composition has the beneficial effects that the usage amount of Ectoine and rare ginsenoside CK can be reduced, so that the cost is saved, and meanwhile, an excellent anti-wrinkle effect is realized.

Description

Anti-wrinkle compositions, their uses and cosmetics Technical Field

[0001] This application relates to the field of cosmetic technology, and in particular to an anti-wrinkle composition, its preparation method, uses, and cosmetics. Background Technology

[0002] Changes in the content and metabolism of hyaluronic acid in the skin are associated with many pathophysiological conditions or drug treatments. Particularly in aging human skin, the content of hyaluronic acid declines linearly with age. The decrease in hyaluronic acid content with age is considered one of the main causes of endogenous skin aging, such as dryness and wrinkles. Hyaluronic acid synthase HAS-1 promotes the synthesis of hyaluronic acid in the skin. Hyaluronic acid is a major component of the extracellular matrix, present throughout the entire skin layer, mainly concentrated in the papillary dermis and basement membrane zone, and plays a role in regulating water balance and providing elasticity to the skin.

[0003] Ginseng, known for its blood-tonifying, qi-boosting, spleen-strengthening, lung-benefiting, blood-nourishing, and fluid-generating properties, has been used as a precious traditional Chinese medicine for thousands of years. Its main active ingredient is ginsenosides. Ginsenosides possess various biological activities, including anti-inflammatory, anti-tumor, anti-aging, blood sugar-lowering, and antioxidant effects. However, the skin has a low absorption rate of ginsenosides in their original form. Ginsenosides are absorbed and utilized in the body through the intestines, but the skin lacks substances that can hydrolyze ginsenosides, thus limiting their effectiveness. Rare ginsenoside extracts prepared through fungal fermentation exhibit stronger anti-inflammatory and antioxidant biological activities and are more easily absorbed and utilized. Rare ginsenoside CK can help the skin produce more hyaluronic acid by increasing the expression of the HAS-1 gene, thereby improving skin dryness and elasticity and preventing skin aging.

[0004] Currently, rare ginsenosides and ectoine are both expensive, resulting in high costs and prices for cosmetics using these ingredients. The composition described above can reduce the amount of ectoine and rare ginsenosides needed, thereby saving costs while achieving excellent anti-wrinkle effects. Summary of the Invention

[0005] In view of the shortcomings of the prior art, the purpose of this application is to provide an anti-wrinkle composition, its preparation method, its use and cosmetics.

[0006] In a first aspect, this application provides an anti-wrinkle composition comprising ginsenoside CK and low molecular weight sodium hyaluronate, wherein the mass ratio of ginsenoside CK to the low molecular weight sodium hyaluronate is 1:(5~100), and the viscosity-average molecular weight of the low molecular weight sodium hyaluronate does not exceed 5000 Daltons.

[0007] Optionally, the mass ratio of the ginsenoside CK to the low molecular weight sodium hyaluronate is 1:(5~50).

[0008] Optionally, the mass ratio of the ginsenoside CK to the low molecular weight sodium hyaluronate is 1:(10~50).

[0009] Secondly, this application provides the use of the anti-wrinkle composition as described above in cosmetics.

[0010] Optionally, the anti-wrinkle composition may synergistically enhance the expression of the HAS1 gene.

[0011] Optionally, the cosmetic product includes at least one of serum, gel, lotion, foundation, or cream.

[0012] Thirdly, this application provides a cosmetic product comprising the aforementioned anti-wrinkle composition.

[0013] Optionally, the ginsenoside CK in the cosmetic has a mass percentage concentration of 0.0001% to 1%.

[0014] Optionally, the low molecular weight sodium hyaluronate in the cosmetic has a mass percentage concentration of 0.01% to 1%.

[0015] The beneficial effects of this application are that the anti-wrinkle composition can reduce the amount of ectoine and ginsenoside CK used, thereby saving costs while achieving excellent anti-wrinkle effects. Detailed Implementation

[0016] The present application will now be described in detail with reference to specific embodiments. These embodiments will help those skilled in the art to further understand the present application, but do not limit the present application in any way. It should be noted that those skilled in the art can make several modifications and improvements without departing from the concept of the present application. These all fall within the protection scope of the present application.

[0017] Examples 1 to 4, Comparative Examples 1 to 9 The raw material formulations of Examples 1 to 4 and Comparative Examples 1 to 9 in this application are shown in Table 1. Among them, Comparative Examples 1 to 7 are single-factor control experiments.

[0018] Anti-wrinkle effects were tested on Examples 1 to 4 and Comparative Examples 1 to 9.

[0019] The testing system included: fibroblasts, provided by Guangdong Boxi Biotechnology Co., Ltd.; main reagents included: DMEM culture medium (Gibco), fetal bovine serum (FBS, Lanzhou Rongye), DMSO (Sigma), RNAiso Plus (Aikerui Biotechnology), reverse transcription kit (Aikerui Biotechnology), fluorescent dye (Aikerui Biotechnology), high, medium, and low molecular weight sodium hyaluronate (Bloomage Biotechnology Co., Ltd., with viscosity-average molecular weights of 1,000,000 Daltons, 5,000 Daltons to 50,000 Daltons, and less than 5,000 Daltons, respectively), and ginsenoside CK (Sanyi Technology Guangzhou Co., Ltd.); main equipment included: CO2 incubator (Thermo, 150I), ultra-clean workbench (Sujing Antai, SW-CJ-1F), microplate reader (BioTek, Epoch), and UVA irradiator (Philips); working solution preparation: the positive control group was DMEM culture medium containing 10% FBS, and all comparative and example samples were dissolved in DMEM culture medium containing 10 wt% FBS.

[0020] The concentrations are shown in Table 1.

[0021] The test method includes the following steps: (1) Cell seeding: at 2×10 5 Fibroblasts were seeded into 6-well plates at a seeding density of cells / well and incubated overnight in a CO2 incubator (37°C, 5 v / v% CO2).

[0022] (2) Drug administration: According to the test grouping in the table above, when the cell deposition rate in the 6-well plate reaches 30%~50%, the drugs are administered to the groups, with 3 replicates for each group. 2 mL of culture medium containing the corresponding concentration of the test substance is added to each well of the sample group; 2 mL of control culture medium is added to the positive control group. After drug administration, the 6-well plate is placed in a CO2 incubator (37℃, 5v / v%CO2) and incubated for 24 h.

[0023] (3) UVA irradiation: All samples were irradiated with UVA. After irradiation, they were placed in a CO2 incubator (37℃, 5v / v%CO2) for 24h.

[0024] (4) Cell collection: After culturing for 24 hours, wash twice with 1 mL / well of PBS, add 1 mL of RNAiso Plis to each well, lyse the cells by pipetting, and collect the sample.

[0025] (5) Gene expression detection: RNA was extracted, reverse transcribed into cDNA, and then detected by real-time quantitative PCR. -△△CT The method is used to calculate the results.

[0026] (6) Statistical analysis of results: Graphpad Prism was used for plotting, and the results are expressed as Mean ± SD. The readings were based on the positive control group (UVA), and the fold increase of HAS1 gene in the positive control was defined as 1. The t-test was used for comparisons between groups. All statistical analyses were two-tailed. P < 0.05 was considered statistically significant, and P < 0.01 was considered extremely statistically significant (as shown in Table 3).

[0027] Table 1. Component content of each embodiment and comparative example.

[0028] Table 2 Component content and test results for each embodiment

[0029] Table 3 Statistical analysis of component content and test results in the examples

[0030] When the target effect does not exceed 100%, the anti-wrinkle synergistic performance data are calculated as follows: E 预测 =(Ea 实际 +Eb 实际 -Ea 实际 ×Eb 实际 )×100%E 预测 : Predicted percentage increase in HAS1 gene expression relative to fold increase in the examples; Ea 实际 : Actual measured values ​​of the relative fold increase in HAS1 gene expression at the same ginsenoside CK concentration in the comparative proportion; Eb 实际 The actual measured values ​​of the relative fold increase in HAS1 gene expression for the same low molecular weight sodium hyaluronate concentration (as shown in Table 2); according to the Bliss Independence model, E 实际 >E 预测 This indicates that the two components have a synergistic effect.

[0031] Example 1 E 预测 The E value of Example 2 was calculated from the data of Comparative Examples 2 and 4. 预测 The E value of Example 3 was calculated from the data of Comparative Examples 1 and 4. 预测 The E value of Example 4 was calculated from the data of Comparative Examples 2 and 5. 预测 Calculated from data of Comparative Examples 1 and 5. Comparative Examples 1 to 7 were single-component administrations, and E was not calculated. 预测Comparative Example 8 replaced the low molecular weight sodium hyaluronate in Example 1 with medium molecular weight sodium hyaluronate, and Comparative Example 9 replaced the low molecular weight sodium hyaluronate in Example 1 with high molecular weight sodium hyaluronate.

[0032] Comparative Examples 1-4, Comparative Example 8, and Comparative Example 9 (E) 预测 and E 实际 Make a collaborative decision: if E 实际 >E 预测 To increase efficiency; if E 实际 <E 预测 , for antagonism; if E 实际 =E 预测 , for addition.

[0033] The test results of Examples 1 to 4 and Comparative Examples 1 to 8 are shown in Table 2. The E value of Example 1... 预测 =(1.01-1)+(1.39-1)-(1.01-1)×(1.39-1)=40%, E in Example 2 预测 =(1.06-1)+(1.39-1)-(1.06-1)×(1.39-1)=43%, E in Example 3 预测 =(1.01-1)+(1.43-1)-(1.01-1)×(1.43-1)=44%, E in Example 4 预测 = (1.06-1) + (1.43-1) - (1.06-1) × (1.43-1) = 46%.

[0034] Taking Example 1 as an example, the combination of 0.025 mg / mL ginsenoside CK and 0.125 mg / mL low molecular weight sodium hyaluronate significantly enhanced HAS1 gene expression, with an increase of E. 实际 =(1.71-1)=71%, E 实际 >E 预测 This demonstrates that 0.025 mg / mL ginsenoside and 0.125 mg / mL low molecular weight sodium hyaluronate have a synergistic effect in enhancing HAS1 gene expression. The combinations of ginsenoside CK and low molecular weight sodium hyaluronate in Examples 2, 3, and 4 also exhibited a synergistic effect in enhancing HAS1 gene expression.

[0035] The results in the table above indicate that the composition of this application can effectively enhance HAS1 gene expression, and that ginsenoside CK and low molecular weight sodium hyaluronate have synergistic anti-aging effects.

[0036] The specific embodiments of this application have been described above. It should be understood that this application is not limited to the specific embodiments described above, and those skilled in the art can make various modifications or variations within the scope of the claims, which do not affect the substantive content of this application.

Claims

1. An anti-wrinkle composition, characterized in that, It includes ginsenoside CK and low molecular weight sodium hyaluronate, wherein the mass ratio of ginsenoside CK to low molecular weight sodium hyaluronate is 1:(5~100), and the viscosity-average molecular weight of low molecular weight sodium hyaluronate does not exceed 5000 Daltons.

2. The anti-wrinkle composition according to claim 1, characterized in that, The mass ratio of the ginsenoside CK to the low molecular weight sodium hyaluronate is 1:(5~50).

3. The anti-wrinkle composition according to claim 2, characterized in that, The mass ratio of the ginsenoside CK to the low molecular weight sodium hyaluronate is 1:(10~50).

4. Use of an anti-wrinkle composition as described in any one of claims 1 to 3 in a cosmetic.

5. The use according to claim 4, characterized in that, The anti-wrinkle composition can synergistically enhance the expression of the HAS1 gene.

6. The use according to claim 4, characterized in that, The cosmetics include at least one of serum, gel, lotion, foundation, or cream.

7. A cosmetic product, characterized in that, The anti-wrinkle composition comprising any one of claims 1 to 3.

8. The cosmetic product according to claim 7, characterized in that, The ginsenoside CK has a mass percentage concentration of 0.0001% to 1% in the cosmetic.

9. The cosmetic product according to claim 7, characterized in that, The low molecular weight sodium hyaluronate in the cosmetic has a mass percentage concentration of 0.01% to 1%.

Images